|
Consolidated Statements Of Operations And Comprehensive Loss (USD $)
In Thousands, except Per Share data, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
|
| Statement Consolidated Statements Of Operations And Comprehensive Loss [Abstract] | |||
| Products and services revenue | $ 47,511biol_ProductsAndServicesRevenue | $ 56,186biol_ProductsAndServicesRevenue | $ 57,191biol_ProductsAndServicesRevenue |
| License fees and royalty revenue | 145biol_LicenseFeesAndRoyaltyRevenue | 244biol_LicenseFeesAndRoyaltyRevenue | 165biol_LicenseFeesAndRoyaltyRevenue |
| Net revenue | 47,656us-gaap_SalesRevenueNet | 56,430us-gaap_SalesRevenueNet | 57,356us-gaap_SalesRevenueNet |
| Cost of revenue | 29,484us-gaap_CostOfRevenue | 34,900us-gaap_CostOfRevenue | 30,878us-gaap_CostOfRevenue |
| Gross profit | 18,172us-gaap_GrossProfit | 21,530us-gaap_GrossProfit | 26,478us-gaap_GrossProfit |
| Operating expenses: | |||
| Sales and marketing | 16,375us-gaap_SellingAndMarketingExpense | 18,682us-gaap_SellingAndMarketingExpense | 16,250us-gaap_SellingAndMarketingExpense |
| General and administrative | 14,854us-gaap_GeneralAndAdministrativeExpense | 9,377us-gaap_GeneralAndAdministrativeExpense | 8,075us-gaap_GeneralAndAdministrativeExpense |
| Engineering and development | 4,577us-gaap_ResearchAndDevelopmentExpense | 4,029us-gaap_ResearchAndDevelopmentExpense | 4,684us-gaap_ResearchAndDevelopmentExpense |
| Excise tax | 307biol_ExciseTax | 438biol_ExciseTax | |
| Total operating expenses | 36,113us-gaap_OperatingExpenses | 32,526us-gaap_OperatingExpenses | 29,009us-gaap_OperatingExpenses |
| Loss from operations | (17,941)us-gaap_OperatingIncomeLoss | (10,996)us-gaap_OperatingIncomeLoss | (2,531)us-gaap_OperatingIncomeLoss |
| Loss on foreign currency transactions | (415)us-gaap_ForeignCurrencyTransactionGainLossBeforeTax | (50)us-gaap_ForeignCurrencyTransactionGainLossBeforeTax | (175)us-gaap_ForeignCurrencyTransactionGainLossBeforeTax |
| Interest expense, net | (458)us-gaap_InterestAndDebtExpense | (600)us-gaap_InterestAndDebtExpense | (239)us-gaap_InterestAndDebtExpense |
| Non-operating loss, net | (873)us-gaap_NonoperatingIncomeExpense | (650)us-gaap_NonoperatingIncomeExpense | (414)us-gaap_NonoperatingIncomeExpense |
| Loss before income tax provision (benefit) | (18,814)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments | (11,646)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments | (2,945)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
| Income tax provision (benefit) | 112us-gaap_IncomeTaxExpenseBenefit | (164)us-gaap_IncomeTaxExpenseBenefit | 111us-gaap_IncomeTaxExpenseBenefit |
| Net loss | (18,926)us-gaap_NetIncomeLoss | (11,482)us-gaap_NetIncomeLoss | (3,056)us-gaap_NetIncomeLoss |
| Other comprehensive income (loss) items: | |||
| Foreign currency translation adjustments | (283)us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax | 46us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax | 40us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax |
| Comprehensive loss | $ (19,209)us-gaap_ComprehensiveIncomeNetOfTax | $ (11,436)us-gaap_ComprehensiveIncomeNetOfTax | $ (3,016)us-gaap_ComprehensiveIncomeNetOfTax |
| Net loss per share: | |||
| Basic | $ (0.45)us-gaap_EarningsPerShareBasic | $ (0.35)us-gaap_EarningsPerShareBasic | $ (0.10)us-gaap_EarningsPerShareBasic |
| Diluted | $ (0.45)us-gaap_EarningsPerShareDiluted | $ (0.35)us-gaap_EarningsPerShareDiluted | $ (0.10)us-gaap_EarningsPerShareDiluted |
| Shares used in the calculation of net loss per share: | |||
| Basic | 42,232us-gaap_WeightedAverageNumberOfSharesOutstandingBasic | 32,768us-gaap_WeightedAverageNumberOfSharesOutstandingBasic | 32,162us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
| Diluted | 42,232us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding | 32,768us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding | 32,162us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
| X | ||||||||||
|
- Definition
Effective for sales beginning January 1, 2013, the Patient Protection and Affordable Care Act imposes a 2.3% medical device excise tax on certain product sales to customers located in the U.S. No definition available.
|
| X | ||||||||||
|
- Definition
Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. No definition available.
|
| X | ||||||||||
|
- Definition
Revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Services revenue may be derived by providing other, non specified, services during the reporting period. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Interest and debt related expenses associated with nonoperating financing activities of the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|